
    
      This is a multicenter trial to evaluate Pembrolizumab for patients with advanced penile
      squamous cell carcinoma following prior chemotherapy. Participating institutions are the
      University of Alabama at Birmingham (coordinating center), M.D. Anderson Cancer Center,
      University of Michigan, University of Minnesota, and Emory University. Patients will receive
      intravenous Pembrolizumab every 3 weeks and undergo a clinical exam. Radiographic scans will
      be done at baseline and every 9 weeks. Therapy will continue until disease progression or
      there are intolerable toxicities.
    
  